AllianceBernstein’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.31M Sell
28,213
-30,367
-52% -$4.55M ﹤0.01% 1621
2026
Q1
$8.08M Buy
58,580
+47,267
+418% +$7.25M ﹤0.01% 1303
2025
Q4
$1.56M Sell
11,313
-62,769
-85% -$8.22M ﹤0.01% 2135
2025
Q3
$9.5M Buy
74,082
+2,110
+3% +$257K ﹤0.01% 1229
2025
Q2
$8.71M Sell
71,972
-36,753
-34% -$4.14M ﹤0.01% 1234
2025
Q1
$12.1M Buy
108,725
+61,567
+131% +$6.55M ﹤0.01% 1072
2024
Q4
$4.59M Buy
47,158
+12,184
+35% +$1.3M ﹤0.01% 1530
2024
Q3
$4.02M Buy
34,974
+12,367
+55% +$1.4M ﹤0.01% 1611
2024
Q2
$2.41M Sell
22,607
-30,176
-57% -$3.03M ﹤0.01% 1841
2024
Q1
$5.11M Sell
52,783
-7,347
-12% -$753K ﹤0.01% 1454
2023
Q4
$6.07M Buy
60,130
+7,703
+15% +$744K ﹤0.01% 1407
2023
Q3
$5.34M Buy
52,427
+20,220
+63% +$2.05M ﹤0.01% 1387
2023
Q2
$3.25M Buy
32,207
+6,328
+24% +$633K ﹤0.01% 1627
2023
Q1
$2.38M Sell
25,879
-869
-3% -$75.9K ﹤0.01% 1773
2022
Q4
$2.43M Buy
26,748
+181
+0.7% +$15.2K ﹤0.01% 1802
2022
Q3
$2.02M Buy
26,567
+554
+2% +$45.9K ﹤0.01% 1882
2022
Q2
$2.2M Sell
26,013
-2,104
-7% -$185K ﹤0.01% 1900
2022
Q1
$2.47M Sell
28,117
-800
-3% -$69.3K ﹤0.01% 1960
2021
Q4
$2.53M Sell
28,917
-154
-0.5% -$12.8K ﹤0.01% 2000
2021
Q3
$2.38M Sell
29,071
-230
-0.8% -$20.7K ﹤0.01% 2061
2021
Q2
$2.67M Sell
29,301
-44,546
-60% -$3.97M ﹤0.01% 2008
2021
Q1
$6.31M Buy
73,847
+41,805
+130% +$3.75M ﹤0.01% 1435
2020
Q4
$3.03M Buy
32,042
+869
+3% +$75.9K ﹤0.01% 1752
2020
Q3
$2.71M Buy
31,173
+1,296
+4% +$112K ﹤0.01% 1675
2020
Q2
$2.61M Buy
29,877
+1,038
+4% +$89.6K ﹤0.01% 1700
2020
Q1
$2.38M Sell
28,839
-694
-2% -$61.9K ﹤0.01% 1580
2019
Q4
$2.8M Buy
29,533
+428
+1% +$38.4K ﹤0.01% 1775
2019
Q3
$2.53M Buy
29,105
+630
+2% +$56.6K ﹤0.01% 1787
2019
Q2
$2.6M Sell
28,475
-98,392
-78% -$8.33M ﹤0.01% 1809
2019
Q1
$10.9M Buy
126,867
+26,502
+26% +$2.13M 0.01% 1021
2018
Q4
$7.72M Sell
100,365
-85,178
-46% -$6.63M 0.01% 1101
2018
Q3
$14.3M Buy
185,543
+127,579
+220% +$9.43M 0.01% 874
2018
Q2
$3.92M Sell
57,964
-1,531
-3% -$106K ﹤0.01% 1421
2018
Q1
$4.31M Sell
59,495
-1,295
-2% -$98.6K ﹤0.01% 1304
2017
Q4
$4.57M Sell
60,790
-19,473
-24% -$1.47M ﹤0.01% 1267
2017
Q3
$6.17M Buy
80,263
+17,205
+27% +$1.3M ﹤0.01% 1119
2017
Q2
$4.72M Buy
63,058
+1,655
+3% +$117K ﹤0.01% 1247
2017
Q1
$4.09M Buy
61,403
+15,714
+34% +$1.05M ﹤0.01% 1316
2016
Q4
$2.98M Sell
45,689
-1,912
-4% -$124K ﹤0.01% 1550
2016
Q3
$3.37M Buy
47,601
+9,358
+24% +$682K ﹤0.01% 1384
2016
Q2
$2.83M Buy
38,243
+5,406
+16% +$373K ﹤0.01% 1423
2016
Q1
$2.13M Buy
32,837
+6,619
+25% +$450K ﹤0.01% 1561
2015
Q4
$2.02M Sell
26,218
-8,583
-25% -$682K ﹤0.01% 1609
2015
Q3
$2.87M Sell
34,801
-16,506
-32% -$1.47M ﹤0.01% 1376
2015
Q2
$4.52M Buy
51,307
+11,935
+30% +$1.09M ﹤0.01% 1167
2015
Q1
$3.48M Buy
39,372
+4,940
+14% +$438K ﹤0.01% 1334
2014
Q4
$2.86M Buy
34,432
+74
+0.2% +$6.13K ﹤0.01% 1470
2014
Q3
$2.9M Sell
34,358
-5,349
-13% -$433K ﹤0.01% 1437
2014
Q2
$3.22M Sell
39,707
-475
-1% -$37.4K ﹤0.01% 1415
2014
Q1
$3.06M Sell
40,182
-3,493
-8% -$255K ﹤0.01% 1411
2013
Q4
$3.15M Buy
43,675
+373
+0.9% +$25.9K ﹤0.01% 1406
2013
Q3
$2.98M Buy
43,302
+6,939
+19% +$459K ﹤0.01% 1396
2013
Q2
$2.3M Buy
+36,363
New +$2.37M ﹤0.01% 1512

Other funds holding NVS

AllianceBernstein's NVS Position: Q2 2026 in Review

AllianceBernstein reduced its Novartis (NVS) stake by 52% in Q2 2026, selling an estimated $4.55M and leaving 28,213 shares worth $4.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

AllianceBernstein first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.3M in Q3 2018. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • AllianceBernstein held 28,213 shares of Novartis worth $4.31M as of Q2 2026.
  • AllianceBernstein sold 30,367 Novartis shares in Q2 2026, an estimated $4.55M.
  • Novartis made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1621 holding.
  • AllianceBernstein first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • AllianceBernstein's Novartis position peaked at $14.3M in Q3 2018.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.